Skip to main content
Signal8

Swedish Orphan Biovitrum AB (BIOVF)

Operating under the ticker BIOVF, Swedish Orphan Biovitrum AB (publ) is a specialized biotechnology company dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products. Its primary therapeutic focus areas encompass hematology, immunology, and a range of genetic and metabolic disorders, with a commercial presence across Europe, North America, and other international markets. The company's diverse portfolio includes medications addressing critical conditions such as hemophilia B (Alprolix) and hemophilia A (Elocta), thrombocytopenia (Doptelet), hemophagocytic lymphohistiocytosis (Gamifant), and hereditary tyrosinemia type-1 (Orfadin). Additionally, it provides Kineret for multiple inflammatory diseases, including cryopyrin-associated periodic syndrome, rheumatoid arthritis, and Still's disease, alongside Synagis for severe lower respiratory tract infections. Sobi's broader product range further comprises various other therapeutics like Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. Beyond its proprietary offerings, Sobi is involved in the development of drug substances for external partners, notably ReFacto AF/Xyntha for Pfizer, as well as advancing BIVV001 for hemophilia A and Nirsevimab, which targets respiratory syncytial virus. A key strategic collaboration exists with Apellis Pharmaceuticals Inc. for the co-development of pegcetacoplan, aimed at treating a spectrum of rare diseases, such as paroxysmal nocturnal hemoglobinuria. The company maintains its headquarters in Solna, Sweden.

Sector: Medical - Pharmaceuticals

Industry: Medical - Pharmaceuticals

Swedish Orphan Biovitrum AB logo

Swedish Orphan Biovitrum AB

OTC:BIOVFHealthcare
CLOSED
Mkt Cap$17.77B
EV-
Float181.53M
O/S348M
VOL100 sh
$ Vol$5K
Inst Own-
SI0.2%
Net Cash/Sh-
EarningsFeb 4 · in 3mo
Dilution
Short interest (FINRA)
0.2%
Oct 30 (21d)

Float 181.53M · Market-data free float

339.2K
Oct 30 (21d)prev 381.9K▼ 11.2%
417.18
Oct 30 (21d)prev 105.04▲ 297.2%
Borrow

The cost to borrow BIOVF shares for a short sale and how many shares are available to borrow, refreshed through the session.

Borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
No fails on record for 16–31 Oct 2026.
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 2026339.2K sh
Oct 15, 2026381.9K sh
Sep 30, 2026330.7K sh
Sep 15, 2026351.5K sh
Aug 31, 2026620.9K sh

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume

Too few published sessions to show a reading in context.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for BIOVF: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 339,170 BIOVF shares were sold short (0.19% of a 181.53M-share float, 417.18 days to cover).